04Jun/13

Parents Fight Organ Donation Law to Save Daughter's Life – Christian Post


Christian Post

Parents Fight Organ Donation Law to Save Daughter’s Life
Christian Post
Sarah Murnaghan, 10, is fighting for her life alongside her parents, who are trying to overturn a law concerning organ donation. Sarah’s age makes her too young to be an adult recipient, and there are considerably fewer juvenile donations of the organ
Family Of Dying Girl Pleads For Changes To Organ Donor PolicyCBS Local
Delco Mom Pleads for Direct Organ Donation to Save ChildPatch.com
Official seeks review of organ donor policyDelaware County Daily Times
Fox News –New York Daily News –KYW Newsradio
all 130 news articles »
04Jun/13

Meet the crusaders for organ donation – Irish Independent


Irish Independent

Meet the crusaders for organ donation
Irish Independent
“If you inform people young, it will just become a done thing,” Clare explains, citing a US study that showed that 90pc of people supported organ donation, but only 30pc held organ donor cards. Her classmate Clodagh Martin found that lack of awareness
Organ donation: Public to be consulted on proposed law changeBBC News
A legacy of lifeSuffolk News-Herald

all 4 news articles »

04Jun/13

Novartis phase III trial shows Afinitor delays tumour growth in HER2 positive … – pharmabiz.com

Novartis phase III trial shows Afinitor delays tumour growth in HER2 positive
pharmabiz.com
Novartis has presented results from a pivotal phase III trial of a treatment regimen including Afinitor (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior
Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor PR Newswire (press release)
Novartis reports positive breast cancer data for AfinitorZenopa
NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays 4-traders (press release)

all 5 news articles »

04Jun/13

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell … – MarketWatch

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell
MarketWatch
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared
MEL200 demonstrated a longer median PFS and OS compared to MPR in the Investor’s Business Daily
ASCO 2012 Multiple Myeloma Update – Day Three: Poster PresentationsThe Myeloma Beacon

all 9 news articles »